top of page

OUR VISION

What we do

chip_edited.png

OUR INSIGHTS

We translate real-time organ physiology into actionable data with our AI platforms, speeding human-relevant drug discovery.

OUR OUTPUT

We generate predictive human data on safety, efficacy, and patient response to de-risk and accelerate drug development.

OUR APPROACH

We work hand in hand with our partners to ensure successful translation of discoveries from human models to the clinic.

Fluorescent Heart.png

DISCOVERY & GENERATION

The MechaniX software suite reconstructs metabolic networks and process dynamics to identify novel targets, generate unique assets, and predict human-relevant toxicity with over 95% accuracy.

Bio-192cut.png

HIGH THROUGHPUT BIOLOGY

Tissue Dynamics' advanced robotic automation platform allows for the formation, tracking, and long-term study of over 20,000 human organoids in parallel. The system eliminates human error and drastically reduces technical variability. 

iso.png

ADVANCED SENSOR TECHNOLOGY

The DynamiX platform enables the real-time readout of human organoid metabolism and function under physiological conditions, providing critical insight into the dynamics and mechanism of disease.  

OUR TECHNOLOGY

Bionic Discovery Platform

sensor.png

Illuminating Drug Development

Massively scalable platform with human focus at every step of drug creation

mitochondria_small.png

OUR SERVICES

Designing Better Drugs

COMPOUND PROFILING & SCREENING

Real-time human organoid screening delivering unmatched functional and metabolic insights for smarter drug decisions

MODEL & ASSAY DEVELOPMENT

Design tailored organoid models with integrated biomarkers and multi-omics endpoints for precise mechanism-of-action and translational insights.

DRUG DEVELOPMENT PARTNERSHIPS

Collaborate with our scientific team to integrate human disease biology, accelerating candidate validation and translation toward clinical success.

SAFETY PHARMACOLOGY & TOXICOLOGY

Assess drug safety via organoid-based toxicology across key human tissues, tracking tissue injury and off-target effects with continuous readouts.

OUR TEAM

Experience that Counts

kobi.png

YAAKOV NAHMIAS

Professor; Founder

nobel.png

ROGER KORNBERG

Professor; Nobel laureate, Stanford

erez.png

EREZ VIGODMAN

Former CEO of TEVA

avner1.png

AVNER EHRLICH

CEO

OUR PARTNERS

Collaborations and Partnerships

partners-10.png
partners-11.png
partners-02.png
partners-01.png
partners-08.png
partners-09.png
partners-05.png
partners-04.png
partners-03.png
partners-06.png
partners-07.png
bottom of page